147 related articles for article (PubMed ID: 34722213)
21. Practices of tablet splitting and dose uniformity of fragments at public hospitals in Ethiopia: A cross-sectional study supported by experimental findings.
Emagn Kasahun A; Joseph NM; Belete A
PLoS One; 2022; 17(12):e0279135. PubMed ID: 36520879
[TBL] [Abstract][Full Text] [Related]
22. Dermatologic adverse effect of subcutaneous furosemide administration in a cat.
Mazzoldi C; Aspidi F; Romito G
Open Vet J; 2023 Aug; 13(8):1027-1031. PubMed ID: 37701668
[TBL] [Abstract][Full Text] [Related]
23. Liquisolid systems to improve the dissolution of furosemide.
Akinlade B; Elkordy AA; Essa EA; Elhagar S
Sci Pharm; 2010; 78(2):325-44. PubMed ID: 21179350
[TBL] [Abstract][Full Text] [Related]
24. Actual Versus Expected Doses of Half Tablets Containing Prescribed Psychoactive Substances: A Systematic Review.
Eserian JK; Lombardo M; Chagas JR; Galduróz JCF
Prim Care Companion CNS Disord; 2018 Feb; 20(1):. PubMed ID: 29469240
[TBL] [Abstract][Full Text] [Related]
25. Effect of personal, food manufacturer, and pet health statements made by a veterinarian during a pet wellness appointment on a dog or cat owner's decision to consider changing their pet's diet.
Alvarez EE; Schultz KK
J Am Vet Med Assoc; 2021 Sep; 259(6):644-650. PubMed ID: 34448614
[TBL] [Abstract][Full Text] [Related]
26. Motivators and barriers for dog and cat owners and veterinary surgeons in the United Kingdom to using preventative medicines.
Belshaw Z; Robinson NJ; Dean RS; Brennan ML
Prev Vet Med; 2018 Jun; 154():95-101. PubMed ID: 29685450
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
28. Elucidating the Splitting Behavior of Tablets to Optimize the Pharmacotherapy in Veterinary Medicine.
Bedogni GR; Pires FQ; Chaker JA; Sa-Barreto LL; Seremeta K; Okulik N; Salomon CJ; Cunha-Filho M
AAPS PharmSciTech; 2021 Feb; 22(2):67. PubMed ID: 33554316
[TBL] [Abstract][Full Text] [Related]
29. Constant rate infusion vs. intermittent bolus administration of IV furosemide in 100 pets with acute left-sided congestive heart failure: A retrospective study.
Ohad DG; Segev Y; Kelmer E; Aroch I; Bdolah-Abram T; Segev G; Klainbart S
Vet J; 2018 Aug; 238():70-75. PubMed ID: 30103918
[TBL] [Abstract][Full Text] [Related]
30. The practice of splitting tablets: cost and therapeutic aspects.
Bachynsky J; Wiens C; Melnychuk K
Pharmacoeconomics; 2002; 20(5):339-46. PubMed ID: 11994043
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Newly Designed and Traditional Punches in Manufacturing of Scored ODTs.
Palugan L; Moutaharrik S; Maroni A; Foppoli AA; Melocchi A; Vecchio C; Gazzaniga A; Cerea M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297490
[TBL] [Abstract][Full Text] [Related]
32. Effect of furosemide oral solution versus furosemide tablets on diuresis and electrolytes in patients with moderate congestive heart failure.
Cohen N; Golik A; Dishi V; Zaidenstein R; Weissgarten J; Averbukh Z; Modai D
Miner Electrolyte Metab; 1996; 22(4):248-52. PubMed ID: 8807629
[TBL] [Abstract][Full Text] [Related]
33. Raman spectroscopy for the analytical quality control of low-dose break-scored tablets.
Gómez DA; Coello J; Maspoch S
J Pharm Biomed Anal; 2016 May; 124():207-215. PubMed ID: 26962721
[TBL] [Abstract][Full Text] [Related]
34. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations.
Ozdemir N; Ordu S; Ozkan Y
Drug Dev Ind Pharm; 2000 Aug; 26(8):857-66. PubMed ID: 10900542
[TBL] [Abstract][Full Text] [Related]
35. Effect of different splitting techniques on the characteristics of divided tablets of five commonly split drug products in Jordan.
Gharaibeh SF; Tahaineh L
Pharm Pract (Granada); 2020; 18(2):1776. PubMed ID: 32377280
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of marketed and formulated furosemide tablets.
Elgindy NA; Ismail AA; Gadalla MA
Pharmazie; 1981 Sep; 36(9):628-30. PubMed ID: 7301904
[TBL] [Abstract][Full Text] [Related]
37. Development and evaluation of a monolithic floating dosage form for furosemide.
Menon A; Ritschel WA; Sakr A
J Pharm Sci; 1994 Feb; 83(2):239-45. PubMed ID: 8169797
[TBL] [Abstract][Full Text] [Related]
38. OPTIMIZATION OF FUROSEMIDE LIQUISOLID TABLETS PREPARATION PROCESS LEADING TO THEIR MASS AND SIZE REDUCTION.
Kurek M; Woyna-Orlewicz K; Khalid MH; Jachowicz R
Acta Pol Pharm; 2016 Sep; 73(5):1325-1331. PubMed ID: 29638072
[TBL] [Abstract][Full Text] [Related]
39. Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets.
Vranić E; Uzunović A
Bosn J Basic Med Sci; 2007 Nov; 7(4):328-34. PubMed ID: 18039191
[TBL] [Abstract][Full Text] [Related]
40. Tablet splitting: a review of weight and content uniformity.
Freeman MK; White W; Iranikhah M
Consult Pharm; 2012 May; 27(5):341-52. PubMed ID: 22591978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
